<DOC>
	<DOC>NCT00293592</DOC>
	<brief_summary>This is a multicenter, randomized, double-blind trial, comparing clinical outcomes after the administration of high-dose dexamethasone versus placebo in patients undergoing heart surgery with the use of cardiopulmonary bypass. The primary endpoint is the occurrence of major complications (including all-cause mortality, myocardial infarction, stroke, renal failure, and prolonged mechanical ventilation) in the first 30 days after surgery.</brief_summary>
	<brief_title>Dexamethasone for Cardiac Surgery Trial</brief_title>
	<detailed_description />
	<mesh_term>Postoperative Complications</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>All types of cardiac surgery in which cardiopulmonary bypass is used Age under 18 years Lifeexpectancy &lt; 6 months Emergency operations Reoperations within the same admission</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Heart surgery</keyword>
	<keyword>Cardiopulmonary bypass</keyword>
	<keyword>Systemic Inflammatory Response Syndrome (SIRS)</keyword>
</DOC>